Pagano, Gennaro http://orcid.org/0000-0002-6247-8988
Taylor, Kirsten I.
Anzures Cabrera, Judith
Simuni, Tanya
Marek, Kenneth
Postuma, Ronald B.
Pavese, Nicola
Stocchi, Fabrizio
Brockmann, Kathrin http://orcid.org/0000-0002-7515-8596
Svoboda, Hanno
Trundell, Dylan
Monnet, Annabelle
Doody, Rachelle
Fontoura, Paulo
Kerchner, Geoffrey A.
Brundin, Patrik
Nikolcheva, Tania
Bonni, Azad
,
,
Funding for this research was provided by:
Roche
Article History
Received: 30 June 2023
Accepted: 23 February 2024
First Online: 15 April 2024
Competing interests
: G.P., K.I.T., A.M., R.D., P.F., G.A.K., P.B., T.N. and A.B. are employees and shareholders of F. Hoffmann-La Roche Ltd. R.D. is also employed by Genentech. P.B. also has ownership interests in Acousort AB, Enterin Inc., Axial Therapeutics and Ryne Bio. J.A.C. and D.T. are employees of Roche Products Ltd and shareholders of F. Hoffmann-La Roche Ltd. H.S. is an employee of Roche Diagnostics GmbH Deutschland and a shareholder of F. Hoffmann-La Roche. In the past 12 months, T.S. has served as a consultant for AskBio, Amneal, Blue Rock Therapeutics, Critical Path for Parkinson’s Consortium, Denali, General Electric, Kyowa, NeuroDerm/Mitsubishi Tanabe Pharma America Inc. (MTPA), Prevail/Lilly, Roche, Sanofi, Sinopia, Takeda and Vanqua Bio. T.S. served on advisory boards for AskBio, Amneal, Biohaven, Denali, GAIN, General Electric, Kyowa, Michael J. Fox Foundation for Parkinson’s Research (MJFF), Neuron23, Parkinson Study Group, Prevail/Lilly and Roche. T.S. has also served as a member of the scientific advisory board of Koneksa, NeuroDerm/MTPA, Sanofi and UCB, has received research funding from Amneal, Biogen, NeuroDerm, Prevail, Roche and UCB and is an investigator for NINDS, MJFF, Parkinson’s Foundation. K.M. is a consultant for MJFF, F. Hoffmann-La Roche Ltd, UCB, Denali, Takeda, Biohaven, Neuron23, Aprinoia, Prothena, Calico, Inhibikase, Invicro, Koneksa and Lilly. R.B.P. reports grants and personal fees from Fonds de la Recherche en Sante, grants from Canadian Institute of Health Research, grants from MJFF, grants from Webster Foundation, personal fees from Biogen, personal fees from Curasen, personal fees from Novartis, personal fees from Eisai, others from Parkinson Canada, grants from National Institute of Health, personal fees from International Parkinson and Movement Disorders Society, personal fees from Merck, personal fees from Vaxxinity, personal fees from Bristol Myers Squibb, personal fees from Clinilabs, personal fees from Ventus, personal fees from Korro and personal fees from Calico. R.B.P. also received consulting fees from Roche for helping plan and interpret the study. N.P. reports participating in advisory boards for Britannia, Boston Scientific, Benevolent AI, Hoffmann-La Roche, Inc. and AbbVie. N.P. also reports receiving honoraria from Britannia, AbbVie, GE Healthcare and Boston Scientific, and grants from the Independent Research Fund Denmark, Danish Parkinson’s Disease Association, Parkinson’s UK, Center of Excellence in Neurodegeneration network award, GE Healthcare Grant, Multiple System Atrophy Trust, Weston Brain Institute, European Union (EU) Joint Program Neurodegenerative Disease Research, EU Horizon 2020 research and Hoffmann-La Roche, Inc. F.S. is a consultant for AbbVie, Bial Pharma, Biogen, F. Hoffmann-La Roche Ltd, H. Lundbeck A S, Mitsubishi Tanabe Pharma America, Inc., Sunovion Pharmaceuticals, Inc., Teva Pharmaceutical Industries, Zambon and Britannia. K.B. has received research funding from the MJFF, the German Society for Parkinsonʼs DPG, the Health Forum Baden Wuerttemberg, the Else Kröner Fresenius Stiftung, the University of Tübingen and from the German Research Foundation DFG. K.B. is a consultant for F. Hoffmann-La Roche Ltd, Vanqua Bio and the MJFF, and has received speaker honoraria from AbbVie, Lundbeck, UCB and Zambon.